Evaluation of acute urinary retention (AUR) incidence and its predicting factors after onabotulinumtoxinA (iBTXA) initial therapy in patients with idiopathic overactive bladder (OAB).
Phase of Trial: Phase IV
Latest Information Update: 18 Aug 2015
At a glance
- Drugs Botulinum toxin A (Primary)
- Indications Overactive bladder
- Focus Adverse reactions
- 18 Aug 2015 New trial record